Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, January 13, 2017

MS Update: Two Pharmaceutical Giants Will Work Together To Treat The Auto Immune Disease


                                                                  
  

Click here to receive MS news via e-mail

As of the present time, there is no known cure to Multiple sclerosis which has baffled experts ever since its emergence. However, that could possibly change in no time as two of the well-known pharmaceutical giants, Sanofi and ImmuNext have recently announced that they have finally come up to an agreement to develop an antibody with the potential to treat a series of autoimmune diseases, including multiple sclerosis (MS) and lupus. The two companies revealingly said that they are currently planning to launch a research collaboration that will allegedly support clinical testing of the drug that will hopefully shed light to the mysterious disease that continues to affect millions of people globally.


According to reports revealed by BioPharma Dive, the said agreement would be able to grant Sanofi with exclusive worldwide manufacturing and marketing rights to ImmuNext's preclinical drug INX-021, a monoclonal antibody that is known to calm a cellular pathway for a protein called CD40L or CD154. Experts believe that the protein has the ability to regulate the immune response and contribute to autoimmune diseases and chronic inflammation if by any chance that it becomes hyperactive.





MS Views and News
Providing educational information, resources and services for those affected by MS
````````````````````````````````````````````````

No comments: